Aspirin decreases the risk of depression in older men with high plasma homocysteine

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Almeida, O P ^a,b,c   Flicker, L ^b,c,d   Yeap, B B ^d,e   Alfonso, H ^a,b   McCaul, K ^b   Hankey, G J ^c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e FREMANTLE HOSPITAL   (Australia)

Author keywords

ageing; aspirin; B vitamins; cardiovascular disease; depression; homocysteine

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CYANOCOBALAMIN; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B COMPLEX; ANTITHROMBOCYTIC AGENT;

AGED; AMINO ACID BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; EDUCATIONAL STATUS; GERIATRIC DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SMOKING; AUSTRALIA; BLOOD; HYPERHOMOCYSTEINEMIA; RISK; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ASPIRIN; AUSTRALIA; CROSS-SECTIONAL STUDIES; DEPRESSION; DEPRESSIVE DISORDER; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LOGISTIC MODELS; MALE; PLATELET AGGREGATION INHIBITORS; RISK; VITAMIN B COMPLEX;

EID: 84873697815     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.79     Document Type: Article

References (33)

1. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull World Health Organ 2001; 79: 1076-1084.
2. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR et al. No health without mental health. Lancet 2007; 370: 859-877.
3. Pirkis J, Pfaff J, Williamson M, Tyson O, Stocks N, Goldney R et al. The community prevalence of depression in older Australians. J Affect Disord 2009; 115: 54-61.
4. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72: 1660-1668.
5. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53.
6. Baldwin R, Jeffries S, Jackson A, Sutcliffe C, Thacker N, Scott M et al. Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med 2004; 34: 125-136.
7. Almeida OP. Vascular depression: myth or reality? Int Psychogeriatr 2008; 20: 645-652.
8. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry 2008; 65: 1286-1294.
9. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry 2006; 11: 352-360.
10. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114-1117.
11. Hankey GJ. Is homocysteine a causal and treatable risk factor for stroke? Lancet Neurol 2007; 6: 751-752.
12. Almeida OP, Flicker L, Norman P, Hankey GJ, Vasikaran S, van Bockxmeer FM et al. Association of cardiovascular risk factors and disease with depression in later life. Am J Geriatr Psychiatry 2007; 15: 506-513.
13. Flicker L, Vasikaran SD, Thomas J, Acres JM, Norman P, Jamrozik K et al. Efficacy of B vitamins in lowering homocysteine in older men: maximal effects for those with B12 deficiency and hyperhomocysteinemia. Stroke 2006; 37: 547-549.
14. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010; 9: 855-865.
15. Taylor MJ, Carney SM, Goodwin GM, Geddes Jr. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol 2004; 18: 251-256.
16. Almeida OP, Marsh K, Alfonso H, Flicker L, Davis TM, Hankey GJ. B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol 2010; 68: 503-510.
17. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
18. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010; 9: 273-284.
19. Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 512-520.
20. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort profile: the Health In Men Study (HIMS). Int J Epidemiol 2009; 38: 48-52.
21. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 1999; 14: 858-865.
22. Alexopoulos GS. Depression in the elderly. Lancet 2005; 365:1961-1970.
23. Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, Glasson EJ et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 2008; 32: 766-777.
24. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. AustNZJ Public Health 1999; 23: 453-459.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
26. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-1139.
27. Hankey GJ, Eikelboom JW, Ho WK, van Bockxmeer FM. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004; 181: 314-318.
28. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378: 584-594.
29. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40:1365-1372.
30. Almeida OP, Alfonso H, Jamrozik K, Hankey GJ, Flicker L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc 2010; 58:990-992.
31. Fiebich BL, Candelario-Jalil E, Mantovani M, Heinzmann M, Akundi RS, Hull M et al. Modulation of catecholamine release from rat striatal slices by the fixed combination of aspirin, paracetamol and caffeine. Pharmacol Res 2006; 53: 391-396.
32. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Homocysteine Reynolds EH. folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69: 228-232.
33. Walker JG, Mackinnon AJ, Batterham P, Jorm AF, Hickie I, McCarthy A et al. Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial. Br J Psychiatry 2010; 197: 45-54.